New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
12:00 EDTBDSIBioDelivery Sciences price target raised to $13 from $9 at Ladenburg
Ladenburg raised its price target on shares of BioDelivery Sciences to $13 from $9 following positive top-line data for one of its BEMA buprenorphine Phase III trials. Ladenburg believes these results portend a high probability for positive results from another ongoing Phase 3 study of the drug in another set of patients and the firm maintains a Buy rating on shares.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
09:02 EDTBDSIAcceptance of NDA for Belbuca triggers $10M milestone payment to BDSI
Subscribe for More Information
07:31 EDTBDSIEndo, BioDelivery Sciences announce acceptance of NDA for Belbuca
Subscribe for More Information
February 20, 2015
08:21 EDTBDSISummer Street still feels Endo could acquire BioDelivery Sciences
Summer Street reiterated its belief that Endo (ENDP) could acquire BioDelivery Sciences (BDSI), its partner on multiple products. The firm says scripts for BioDelivery's Bunavail continue to trend in the right direction. It reiterates a Buy rating on the stock with a $25 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use